1149 related articles for article (PubMed ID: 18384820)
1. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
[TBL] [Abstract][Full Text] [Related]
2. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
3. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with the opioid antagonist naltrexone favours the coupling of spinal cord μ-opioid receptors to Gαz protein subunits.
Valdizán EM; Díaz A; Pilar-Cuéllar F; Lantero A; Mostany R; Villar AV; Laorden ML; Hurlé MA
Neuropharmacology; 2012 Feb; 62(2):757-64. PubMed ID: 21903117
[TBL] [Abstract][Full Text] [Related]
5. Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.
Clark MJ; Neubig RR; Traynor JR
J Pharmacol Exp Ther; 2004 Jul; 310(1):215-22. PubMed ID: 15014136
[TBL] [Abstract][Full Text] [Related]
6. Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Tsai RY; Tai YH; Tzeng JI; Cherng CH; Yeh CC; Wong CS
Neuroscience; 2009 Dec; 164(2):435-43. PubMed ID: 19682558
[TBL] [Abstract][Full Text] [Related]
7. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle.
Murthy KS; Makhlouf GM
Mol Pharmacol; 1996 Oct; 50(4):870-7. PubMed ID: 8863832
[TBL] [Abstract][Full Text] [Related]
8. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
9. G(z) can mediate the acute actions of mu- and kappa-opioids but is not involved in opioid-induced adenylyl cyclase supersensitization.
Tso PH; Wong YH
J Pharmacol Exp Ther; 2000 Oct; 295(1):168-76. PubMed ID: 10991975
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.
Clark MJ; Furman CA; Gilson TD; Traynor JR
J Pharmacol Exp Ther; 2006 May; 317(2):858-64. PubMed ID: 16436499
[TBL] [Abstract][Full Text] [Related]
11. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
Zhang L; Tetrault J; Wang W; Loh HH; Law PY
Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132
[TBL] [Abstract][Full Text] [Related]
12. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
13. Mu-opioid receptor regulation during opioid tolerance and supersensitivity in rat central nervous system.
Diaz A; Ruiz F; Flórez J; Hurlé MA; Pazos A
J Pharmacol Exp Ther; 1995 Sep; 274(3):1545-51. PubMed ID: 7562532
[TBL] [Abstract][Full Text] [Related]
14. mu-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase.
Yoshimura M; Ikeda H; Tabakoff B
Mol Pharmacol; 1996 Jul; 50(1):43-51. PubMed ID: 8700117
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory GTP-binding regulatory protein Gi3 can couple angiotensin II receptors to inhibition of adenylyl cyclase in hepatocytes.
Pobiner BF; Northup JK; Bauer PH; Fraser ED; Garrison JC
Mol Pharmacol; 1991 Aug; 40(2):156-67. PubMed ID: 1908548
[TBL] [Abstract][Full Text] [Related]
16. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
17. Regulation of dihydropyridine-sensitive Ca++ channels during opioid tolerance and supersensitivity in rats.
Díaz A; Ruíz F; Flórez J; Pazos A; Hurlé MA
J Pharmacol Exp Ther; 1995 Sep; 274(3):1538-44. PubMed ID: 7562531
[TBL] [Abstract][Full Text] [Related]
18. Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein.
Wang HY; Burns LH
J Neurobiol; 2006 Oct; 66(12):1302-10. PubMed ID: 16967511
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
Szücs M; Boda K; Gintzler AR
J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
